driver mutations in mpns
Published 2 years ago • 371 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
2:07
the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
-
4:50
timing of driver mutations and clonal dynamics in mpns: a new paradigm for blood cancer development
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:27
tp53 mutation in mpns and investigating lsd1 inhibition in tp53-mutant murine models
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
1:03
personalizing aml treatment by targeting mrd mutations
-
12:26
mds/mpn 2022 updates
-
6:42
analytical variation: imprecision and bias
-
7:54
patient/caregiver stories - living with mds
-
2:43
the management of advanced phase mpns
-
2:47
clinical and prognostic implications of wt1 mutations in de novo and r/r aml
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
1:51
checkpoint inhibition in the treatment of mpns
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:26
braf-mutated aml is associated with poor prognosis and myelodysplasia-related mutations
-
1:33
prognostic impact of wt1 mutations in newly diagnosed and r/r aml
-
0:52
genomic profiling at diagnosis of myeloid neoplasms
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:26
current and emerging prognostic factors for mds/mpn
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis